Tirzepatide vs Semaglutide: Which GLP-1 Actually Wins?

You've been approved for a GLP-1 prescription and your clinic is offering you a choice. Semaglutide at roughly $200–$250/month through a telehealth compounding program, or tirzepatide at $300–$400/month for the same route. The prescriber says both work. The internet says tirzepatide is better. Your insurance, if it covers either, may have already made the decision for you. But if it hasn't — and for most people it hasn't — this is a real financial and clinical question that deserves a direct answer.

---

The Mechanism Gap Is Real

Semaglutide is a GLP-1 receptor agonist. Tirzepatide is a dual GIP/GLP-1 receptor agonist — it activates both glucose-dependent insulinotropic polypeptide and GLP-1 pathways simultaneously. That dual action isn't marketing language; it's the structural reason tirzepatide outperforms semaglutide in head-to-head data. GIP receptors in adipose tissue appear to amplify fat-storage inhibition when combined with GLP-1 signalling, which is the working hypothesis behind why the trial numbers diverge as sharply as they do.

---

What the Clinical Trials Actually Show

The SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM) — 2,539 adults with obesity but without diabetes — found that participants on tirzepatide 15 mg lost a mean of 20.9% of body weight over 72 weeks. The STEP 1 trial (Wilding et al., 2021, NEJM), using semaglutide 2.4 mg weekly in a comparable population of 1,961 adults, produced a mean weight loss of 14.9% over 68 weeks. That's a 6-percentage-point gap on a similar timeline. For someone starting at 250 lbs, that's the difference between losing approximately 37 lbs versus approximately 52 lbs.

The SURMOUNT-5 trial, published in 2025, provided the first randomised head-to-head data: tirzepatide produced approximately 47% greater relative weight loss than semaglutide 2.4 mg over 72 weeks in adults with obesity or overweight.

---

Side Effect Profiles: Mostly Parallel, Some Divergence

Nausea, vomiting, diarrhea, and constipation are the dominant side effects of both drugs, and neither is obviously gentler. In STEP 1, roughly 44% of semaglutide patients reported nausea; in SURMOUNT-1, the figure was approximately 31% for tirzepatide — though cross-trial comparisons carry limitations given protocol differences.

Hypoglycaemia risk with tirzepatide is marginally higher in people with type 2 diabetes due to the additive GIP effect on insulin secretion; this is dose-dependent and more relevant to diabetic populations than the general obesity cohort most compounding patients belong to. For patients who are needle-averse, some clinics — Shed (formerly ShedRx) being the most prominent example — offer both drugs in sublingual lozenge form, which sidesteps the injection question without switching medications.

---

The Cost Reality in Mid-2026

Brand-name Zepbound (tirzepatide) lists at approximately $1,059/month before discounts; Wegovy (semaglutide 2.4 mg) runs around $1,349/month at full retail. Neither reflects what most patients actually pay, but the spread matters for anyone uninsured or paying out of pocket.

Compounded versions — still accessible through FDA-registered outsourcing facilities for some formulations — bring tirzepatide down to $300–$450/month and semaglutide to $150–$250/month through most telehealth platforms. That $100–$200 monthly differential becomes $1,200–$2,400 over a year, which is a legitimate reason some patients choose semaglutide even when the efficacy data favours tirzepatide. The best online GLP-1 programs comparison breaks down what's included beyond the sticker price — monitoring frequency, titration support, and whether metabolic labs are bundled.

---

Who Should Lean Toward Which

Tirzepatide makes more clinical sense for: people with type 2 diabetes (both drugs are FDA-approved for T2D, but tirzepatide's glycaemic control data is stronger across the SURPASS trial series); people whose primary goal is maximum weight loss and who can absorb the cost difference; and anyone who tried semaglutide and plateaued — switching mechanisms sometimes restarts progress, though the evidence base for that specific use case remains observational.

Semaglutide holds up well for: cost-constrained patients who want proven efficacy without the premium; people who tolerated semaglutide previously and are restarting; and anyone whose insurer covers Wegovy but not Zepbound. Cardiovascular outcome data for semaglutide is also more mature — the SELECT trial (Lincoff et al., 2023, NEJM) showed a 20% reduction in major adverse cardiovascular events in non-diabetic adults with obesity and established CVD, a dataset tirzepatide is still building toward with its SURPASS-CVOT results pending full publication.

---

The Honest Takeaway

Tirzepatide wins on weight loss efficacy — the SURMOUNT-5 head-to-head trial confirmed it, and the dual GIP/GLP-1 mechanism explains the gap. Semaglutide wins on cost, cardiovascular evidence depth, and availability. If outcomes are the only variable, tirzepatide is the stronger drug for weight reduction. If the $100–$200 monthly difference would compromise adherence through months four to six — where most real-world results accumulate — semaglutide at 2.4 mg is still producing 14.9% mean body weight reduction in controlled trials, which is not a consolation prize.

The more useful question is which drug you'll stay on at a therapeutic dose for twelve months. You can compare GLP-1 providers side by side to find programs that offer both, with pricing transparent enough to make that decision without a phone call.

---

Peptide Clinic Finder is a comparison platform. The author may receive compensation if you sign up through links on our partner pages.

---